Halozyme’s customer web: licensing revenue, manufacturing services and durable royalties

Halozyme monetizes a dual model: licensed drug‑delivery technology (ENHANZE® and Hypercon™) that generates royalties and milestone income from big pharma partners, plus direct sales and manufacturing of proprietary and device products (Hylenex®, XYOSTED®, auto‑injectors). That mix produces high-margin recurring royalties alongside episodic milestone payments and product sales, with material customer concentration and meaningful government and geographic exposure. For deeper signal extraction on counterparties and contract types see NullExposure. https://nullexposure.com/

Simple commercial thesis: platform economics with concentrated counterparties

Halozyme’s core asset is an enzymatic excipient (rHuPH20) and related platforms that enable subcutaneous delivery of biologics. The company earns royalties and milestones from licensing ENHANZE®, upfront and milestone payments for Hypercon™, and product/device sales and supply fees where it manufactures or supplies drug‑delivery hardware. Royalties scale with partner product sales, so Halozyme’s revenue growth is levered to commercial take‑off at a small set of large pharma partners.

What shapes Halozyme’s operating model

Several company‑level constraints define how customers transact with Halozyme:

• Licensing is the primary contract type. Halozyme repeatedly states it recognizes royalties and license fees as core revenue — this drives a capital‑efficient, variable margin model tied to partner commercialization rather than unit manufacturing alone.
• Long‑term, framework and supply contracts coexist. The company records multi‑year unfulfilled purchase orders and convertible note proceeds that support long‑dated commitments; wholesalers and distribution are managed under master agreements.
• Role diversity: licensor, manufacturer, seller and distributor. Halozyme often acts as licensor for ENHANZE® while also manufacturing devices and supplying bulk rHuPH20 or auto‑injectors to partners.
• Geographic concentration—North America and EMEA dominate revenue but APAC regulatory approvals are material to growth. Halozyme hedges Swiss franc denominated royalty risk and highlights EMEA/US revenue concentration.
• Counterparty and reimbursement risk. Sales depend on payer coverage, government purchasing (including VA/CMS exposure) and a handful of large enterprise customers that drive material revenue buckets (>$100m partner exposure disclosed).
• Where explicit in filings, Teva and Otter are named in license and supply agreements, which places them in the licensor/manufacturer categories in Halozyme’s disclosures (10‑K, FY2024 and supply agreements).

These features combine to create a high‑leverage royalty stream but leave Halozyme exposed to partner product performance and policy changes in reimbursement.

Customer map — what each relationship means for investors

Teva Pharmaceutical Industries, Ltd.

Halozyme has commercialized auto‑injector products with Teva and historically licensed multi‑dose pen technology to Teva, generating upfronts, milestones and royalties tied to Teva’s generic launches. Source: Halozyme 2024 10‑K (FY2024).

Otter Pharmaceuticals, LLC

Halozyme granted Otter an exclusive license for OTREXUP and entered a supply agreement to manufacture and assemble the auto‑injection system and prefilled syringe components. Source: Halozyme 2024 10‑K (FY2024).

EPC

Industry coverage notes Halozyme’s use of AI‑powered technology scouting on R&D, cited in broader conversation about operations and innovation. This is a capability reference rather than a commercial revenue stream. Source: KR‑Asia article on corporate operations (May 2026).

ACAD (Acadia Pharmaceuticals / related)

Halozyme will manufacture commercial stick‑pack drug product (trofinetide DAYBUE STIX) for the U.S. market — a supplier/manufacturer engagement that converts Halozyme’s capabilities into commercial revenue. Source: Acadia 2025 filing (FY2025).

Skye Bioscience (Skye / SKYE)

Skye licensed ENHANZE® to develop a subcutaneous formulation (nimacimab) and Halozyme commentary highlights this as a win expanding ENHANZE beyond oncology. Source: Skye press releases and analyst coverage (Mar 2026).

Vertex Pharmaceuticals (VRTX)

Halozyme’s Hypercon™ business entered a global exclusive collaboration and license agreement with Vertex; Vertex agreed to reimburse Halozyme $15 million in advance and potentially pay milestones/royalties. Source: Vertex collaboration press coverage and Halozyme announcements (Apr–May 2026).

Johnson & Johnson (JNJ)

Halozyme receives royalties from J&J for subcutaneous DARZALEX (daratumumab); J&J’s DARZALEX sales remain a major royalty driver for Halozyme. Source: Halozyme Q4 2025 earnings call and subsequent press coverage (Mar 2026).

argenx (ARGX / ARGN)

argenx uses ENHANZE® in VYVGART Hytrulo (subcutaneous efgartigimod + rHuPH20); strong uptake materially increased Halozyme’s royalty revenue. Source: argenx press releases and Halozyme earnings commentary (2025–2026).

Roche (RHHBY / Roche)

Roche’s PHESGO (HER2 therapy) uses ENHANZE® and delivered meaningful sales growth that translated into rising royalties for Halozyme. Source: Halozyme Q4 2025 earnings commentary and press (Mar 2026).

ABOS (Acumen Pharmaceuticals)

Acumen is developing a subcutaneous formulation of sabirnetug using ENHANZE® and has arrangements with Halozyme for clinical/commercial supplies of active ingredient and licensing terms. Source: Acumen press releases and SEC filings (2025–2026).

ViiV Healthcare

ViiV is listed among leading partners licensed to use ENHANZE®, indicating potential future royalty streams tied to ViiV product commercialization. Source: Halozyme investor communications and sector coverage (2026).

Viatris / McDermott Laboratories Limited (VTRS / McDermott)

Halozyme signed a commercial licensing and supply agreement with Viatris affiliate McDermott for small volume auto‑injectors; McDermott is a distribution/manufacturing partner in select product lines. Source: Halozyme earnings call and company releases (Q4 2025).

Takeda (TAK)

Halozyme entered a global ENHANZE collaboration and exclusive license with Takeda for vedolizumab (ENTYVIO), providing upfronts, milestone and low‑to‑mid single‑digit royalties; approvals in multiple jurisdictions bolster recurring royalties. Source: Takeda/Halozyme coverage and analyst notes (Dec 2025–2026).

AbbVie (ABBV)

AbbVie is listed among ENHANZE licensees, suggesting potential medium‑term royalty exposure as partner pipelines mature. Source: Halozyme investor materials (2026).

Bristol‑Myers Squibb (BMY)

BMS commercialized OPDIVO Qvantig with ENHANZE®, produced milestone and royalty payments and reported growing sales of the SC product. Source: Halozyme earnings call and press coverage (2025–2026).

Eli Lilly (LLY)

Lilly is cited as a licensee of ENHANZE®, representing another large pharma counterparty that can generate royalties if co‑formulated products reach scale. Source: Halozyme investor statements and industry reports (2026).

Pfizer (PFE)

Pfizer appears in Halozyme partner lists as a licensee of ENHANZE®, positioning it as a potential royalty contributor pending product commercialization. Source: Halozyme press summaries (2026).

Janssen

Janssen has used ENHANZE® in development and regulatory filings (e.g., RYBREVANT SC submissions), indicating active collaboration and future royalty potential. Source: EMA/FDA submission coverage and Halozyme filings (2024–2026).

Chugai Pharmaceutical

Chugai is included among licensing partners and represents further geographic diversification into Japan and Asia for ENHANZE® collaborations. Source: Halozyme investor materials (2026).

Merus N.V. (MRUS)

Merus has been cited as a recent partner deal contributing to Halozyme’s expanded commercial pipeline and royalty prospects. Source: Market coverage following 2025–2026 deal announcements (Mar 2026).

Hypercon (platform)

Hypercon™ is Halozyme’s newer technology platform; licensing of Hypercon to partners (including Vertex, Janssen and Lilly per disclosures) opens a separate milestone/royalty vector distinct from ENHANZE®. Source: Halozyme announcements and press coverage (Apr 2026).

Surf Bio

Surf Bio is identified alongside Hypercon as an emerging partner whose agreements could contribute milestone and royalty income as programs advance. Source: Analyst coverage and Halozyme investor commentary (May 2026).

Investment implications: concentrated upside, concentrated risk

• Positive: Halozyme’s model delivers high operating leverage — royalty upside scales with partner blockbusters (Darzalex, Phesgo, VYVGART). Hypercon and new licensing wins add incremental optionality.
• Risks: Revenue concentration with a handful of large partners, payer/government reimbursement exposure, and execution risk on early Hypercon programs are the primary downside vectors.
• Operational posture: Halozyme operates as a long‑term licensor and selective manufacturer, with framework supply agreements and hedges to manage FX on Swiss franc royalties.

For a structured view of counterparties, contract types and spend bands used in credit and supplier risk analysis, review detailed signal extracts at NullExposure. https://nullexposure.com/

Bold takeaway: Halozyme is a platform‑first company whose earnings trajectory is driven by partner product adoption; investors should weigh accelerating royalty growth against concentrated counterparty and reimbursement risk.